- Center on Health Equity & Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Dr Alan Menter Discusses 2022 Psoriasis Guideline Updates
Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.
Alan Menter, MD, chairman of dermatology, Baylor University Medical Center, discussed some of the updated psoriasis guidelines at the 2022 American Academy of Dermatology Annual Meeting.
Transcript
What are some of the updated psoriasis guidelines and recommendations for 2022, in relation to cardiovascular comorbidities?
The old theory that coronary artery disease is just caused by cholesterol is no longer true; it's caused by inflammation. Inflammation in the coronary artery is very similar to the inflammation in psoriasis, so improving the skin, we do believe, will improve coronary artery disease.
I chaired—co-chaired, there was 2 of us who chaired—the guidelines that we published in 2019 and 2020 in JAAD [Joint American Academy of Dermatology], and we had 6 papers, all of which were about 70 pages long. One of the guidelines related to coronary artery disease. We are relatively up to date with the fact that coronary artery disease is now inflammation driven, very similar inflammation to psoriasis, and not just driven by cholesterol.
Could On-Body Delivery of Isatuximab Bring More Competition to Anti-CD38 Myeloma Treatment?
June 6th 2025Results for IRAKLIA show noninferiority for Sanofi's on-body delivery system for isatuximab, compared with IV administration. Patients overwhelmingly preferred the hands-free delivery option.
Read More
Laundromats as a New Frontier in Community Health, Medicaid Outreach
May 29th 2025Lindsey Leininger, PhD, and Allister Chang, MPA, highlight the potential of laundromats as accessible, community-based settings to support Medicaid outreach, foster trust, and connect families with essential health and social services.
Listen
Zanubrutinib Shows Durable Benefit for High-Risk CLL/SLL at 5 Years in SEQUOIA Trial
June 6th 2025Zanubrutinib showed long-term efficacy in patients with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) and deletion of the 17p chromosome, with progression-free survival similar to patients without high-risk disease characteristics.
Read More
Real-World Data Support Luspatercept vs ESAs for Anemia in Lower-Risk MDS
June 5th 2025Patients with myelodysplastic syndrome (MDS) who received luspatercept showed greater hemoglobin gains and transfusion independence compared with erythropoiesis-stimulating agents (ESAs) in a real-world analysis.
Read More
At EHA 2025, Hematology Discussions Will Stretch Across Lifespans and Locations
June 5th 2025The 2025 European Hematology Association (EHA) Congress, convening virtually and in Milan, Italy, from June 12 to June 15, 2025, will feature a revamped program structure for the meeting’s 30th anniversary while maintaining ample opportunities to network, debate, and absorb practice-changing findings in hematology and oncology.
Read More
